Etifoxine (Stresam™) is an anxiety medication sold in France since 1979, and more than 25 other countries around the world. Clinically, it has shown rate of onset and efficacy equivalent to Xanax and Ativan, two of the world’s top selling benzodiazepines, but without the sedation, cognitive impairment, withdrawal effects or abuse. To view a history of the drug, click here.
The unique combination of the drug’s selective effects at GABA channels, coupled with the ability to substantially increase the levels of important, natural neurosteroids (like allopregnanolone), give the drug an unrivaled anxiolytic profile of fast onset without the dangers or typical side-effects of benzodiazepines. Upregulation of neuroactive steroids by etifoxine may also account for its recently discovered neurotrophic, neuroprotective and anti-inflammatory properties. The drug has demonstrated efficacy in a large number of animal models of neuropathic and inflammatory pain, multiple sclerosis, epilepsy, Alzheimer’s disease, stroke, traumatic brain injury, nerve/spinal cord injury and retinal/macular degeneration.